ASSET PURCHASE AGREEMENT (Details) - USD ($)		1 Months Ended	12 Months Ended
	Aug. 07, 2019	Aug. 31, 2019	Sep. 30, 2019	Sep. 30, 2018
Asset Purchase Agreement [Line Items]
Purchase price for assets acquired			$ 67,438	$ 266,008
Common stock value			1,200	753
Research and Development Expense			2,967,278	$ 2,751,578
Asset Purchase Agreement
Asset Purchase Agreement [Line Items]
Research and Development Expense			345,332
Contingent consideration liability			$ 0
Asset Purchase Agreement | Vitatex, Inc | LineaRx, Inc.
Asset Purchase Agreement [Line Items]
Purchase price for assets acquired	$ 500,000
Initial payment at closing using common stock	300,000
Payments for issuance of common stock before September 30, 2019	100,000
Payments for issuance of common stock before December 31, 2019	100,000
Outstanding cash and/or equity obligations	11,710
Reduction in cash payment on outstanding cash and equity obligations	88,290
Additional performance-based equity distributions	500,000
Common stock value	150,000	$ 113,132
Common stock due on occurrence of completing program filings	250,000
Threshold limit of Assets yield in gross revenue	100,000
Threshold limit of Assets yield in additional gross revenue	$ 200,000
Percentage of common stock issued		2.00%